If these policy shifts are successful, they could dramatically expand obesity drug coverage for millions of Americans
The FDA has received reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded semaglutide
Data from the ORION study, presented at the Obesity Medicine Associations 2026 annual conference, showed that oral semaglutide 25 mg was associated with significantly greater mean weight loss than orforglipron in a population-adjusted indirect treatment comparison
But if your storage conditions are even slightly off, every single day chips away at the compound you paid good money for
Younger patients with better skin elasticity typically experience less pronounced sagging compared to older individuals or those who have lost weight previously
There are no published clinical trials testing Kind Patches against placebo